These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24558627)

  • 21. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hypo- and hypernatremia].
    Palm C; Wagner A; Gross P
    Dtsch Med Wochenschr; 2011 Jan; 136(1-2):29-33. PubMed ID: 21181613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.
    Praharaj DL; Anand AC
    J Clin Exp Hepatol; 2022; 12(2):575-594. PubMed ID: 35535075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaptans: A new option in the management of hyponatremia.
    Aditya S; Rattan A
    Int J Appl Basic Med Res; 2012 Jul; 2(2):77-83. PubMed ID: 23776817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
    Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms, risks, and new treatment options for hyponatremia.
    Ghali JK
    Cardiology; 2008; 111(3):147-57. PubMed ID: 18434717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolvaptan and its potential in the treatment of hyponatremia.
    Dixon MB; Lien YH
    Ther Clin Risk Manag; 2008 Dec; 4(6):1149-55. PubMed ID: 19337422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients.
    Ishikawa S; Fujita N; Fujisawa G; Tsuboi Y; Sakuma N; Okada K; Saito T
    Endocr J; 1996 Feb; 43(1):101-8. PubMed ID: 8732459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonosmotic secretion of arginine vasopressin and salt loss in hyponatremia in Kawasaki disease.
    Miura K; Harita Y; Takahashi N; Tsurumi H; Yasudo H; Isojima T; Hirata Y; Inuzuka R; Takizawa K; Toyofuku E; Nishimoto H; Takamizawa M; Ando T; Sugawa M; Yanagisawa A; Inatomi J; Nogimori Y; Kinumaki A; Namai Y; Hattori M; Oka A
    Pediatr Int; 2020 Mar; 62(3):363-370. PubMed ID: 31657491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans.
    Malhotra I; Gopinath S; Janga KC; Greenberg S; Sharma SK; Tarkovsky R
    Case Rep Endocrinol; 2014; 2014():807054. PubMed ID: 24511399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrolytes: Sodium Disorders.
    Braun MM; Mahowald M
    FP Essent; 2017 Aug; 459():11-20. PubMed ID: 28806046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia.
    Bulloch MN; Pinner NA
    Expert Rev Clin Pharmacol; 2010 Sep; 3(5):601-12. PubMed ID: 22111741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects.
    Ishikawa Se ; Saito T; Fukagawa A; Higashiyama M; Nakamura T; Kusaka I; Nagasaka S; Honda K; Saito T
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1665-71. PubMed ID: 11297601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyponatremia: a problem-solving approach to clinical cases.
    Assadi F
    J Nephrol; 2012; 25(4):473-80. PubMed ID: 22307436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Verbalis JG; Greenberg A; Burst V; Haymann JP; Johannsson G; Peri A; Poch E; Chiodo JA; Dave J
    Am J Med; 2016 May; 129(5):537.e9-537.e23. PubMed ID: 26584969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with Tolvaptan for Euvolemic and Hypervolemic Hyponatremia in the Acute Care Setting.
    Olin JL; Mitchell G; Cremisi H
    Hosp Pharm; 2015 May; 50(5):380-5. PubMed ID: 26405324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopressin receptor antagonists and their role in clinical medicine.
    Narayen G; Mandal SN
    Indian J Endocrinol Metab; 2012 Mar; 16(2):183-91. PubMed ID: 22470853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasopressin antagonists: role in the management of hyponatremia.
    Yeates KE; Morton AR
    Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.